Compare · NKTX vs NVO
NKTX vs NVO
Side-by-side comparison of Nkarta Inc. (NKTX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NKTX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 1066.7x NKTX ($171.7M).
- Over the past year, NKTX is up 28.1% and NVO is down 45.7% - NKTX leads by 73.7 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 4 for NKTX).
- NVO has more recent analyst coverage (25 ratings vs 13 for NKTX).
- Company
- Nkarta Inc.
- Novo Nordisk A/S
- Price
- $2.40-4.58%
- $41.01-4.51%
- Market cap
- $171.7M
- $183.15B
- 1M return
- -23.73%
- -10.44%
- 1Y return
- +28.07%
- -45.66%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 4
- 8
- Recent ratings
- 13
- 25
Nkarta Inc.
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was incorporated in 2015 and is based in South San Francisco, California.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NKTX
- Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet
- The $13 Million Company Teaching the Immune System to Hunt Cancer
- Amendment: SEC Form SCHEDULE 13D/A filed by Nkarta Inc.
- Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes
- SEC Form 10-Q filed by Nkarta Inc.
- Nkarta Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights
- SEC Form DEFA14A filed by Nkarta Inc.
- SEC Form DEF 14A filed by Nkarta Inc.
- Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care